Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F DiPersio

Showing results (21-30 of 342) with videos related to

Pageof 35
Sort By:
The New England Journal of Medicine|June 17, 2026
Stemness as the Engine of Checkpoint DurabilityRichard S Hotchkiss, John F DiPersio
Disease Models & Mechanisms|May 12, 2011
Mouse models of graft-versus-host disease: advances and limitationsMark A Schroeder, John F DiPersio
Cancer|January 30, 2014
Genomic tools in acute myeloid leukemia: From the bench to the bedsideBrian S White, John F DiPersio
Best Practice & Research. Clinical Haematology|November 30, 2019
Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignanciesMathew L Cooper, John F DiPersio
Journal of Leukocyte Biology|October 27, 2011
Mobilization of hematopoietic stem and leukemia cellsMark A Schroeder, John F DiPersio
Current Opinion in Hematology|October 4, 2008
Total body irradiation before an allogeneic stem cell transplantation: is there a magic dose?Douglas R Adkins, John F DiPersio
Clinical Lymphoma, Myeloma & Leukemia|September 1, 2020
Immunotherapy for T-Cell ALL and T-Cell NHLJohn F DiPersio, Karl Staser, Matthew Cooper
Oncotarget|December 6, 2018
Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHDKidist Ashami, John F DiPersio, Jaebok Choi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2003
Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?Amanda Cashen, John F DiPersio, Hanna Khoury
Frontiers in Oncology|October 5, 2020
Targeting CXCR4 in AML and ALLDaniel Cancilla, Michael P Rettig, John F DiPersio
Pageof 35

Showing results (21-30 of 342) with videos related to

Sort By:
Pageof 35
The New England Journal of Medicine|June 17, 2026
Stemness as the Engine of Checkpoint DurabilityRichard S Hotchkiss, John F DiPersio
Disease Models & Mechanisms|May 12, 2011
Mouse models of graft-versus-host disease: advances and limitationsMark A Schroeder, John F DiPersio
Cancer|January 30, 2014
Genomic tools in acute myeloid leukemia: From the bench to the bedsideBrian S White, John F DiPersio
Best Practice & Research. Clinical Haematology|November 30, 2019
Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignanciesMathew L Cooper, John F DiPersio
Journal of Leukocyte Biology|October 27, 2011
Mobilization of hematopoietic stem and leukemia cellsMark A Schroeder, John F DiPersio
Current Opinion in Hematology|October 4, 2008
Total body irradiation before an allogeneic stem cell transplantation: is there a magic dose?Douglas R Adkins, John F DiPersio
Clinical Lymphoma, Myeloma & Leukemia|September 1, 2020
Immunotherapy for T-Cell ALL and T-Cell NHLJohn F DiPersio, Karl Staser, Matthew Cooper
Oncotarget|December 6, 2018
Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHDKidist Ashami, John F DiPersio, Jaebok Choi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2003
Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?Amanda Cashen, John F DiPersio, Hanna Khoury
Frontiers in Oncology|October 5, 2020
Targeting CXCR4 in AML and ALLDaniel Cancilla, Michael P Rettig, John F DiPersio
Pageof 35